China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
This article was originally published in PharmAsia News
Executive Summary
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
You may also be interested in...
WuXi Forms JV With PRA To Expand Clinical Services In China
WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.
Charles River Strikes Back In China With Research Models Business
After reassessing its China strategy, Charles River makes a new push by acquiring Vital River, the largest supplier of laboratory animals in China.
Mindray And WuXi PharmaTech’s Growth Strategy In 2Q: China Earnings Roundup (Part 1)
PharmAsia News takes a closer look at how Chinese healthcare companies have fared against the backdrop of a global economic slowdown, starting with two of the country’s leading companies in their respective industries.